In the context of glioma, the investigation of Zhang et al. [39] discloses that diminished TGF-β receptor capability, induced by inhibitors, heightens TGF-β ligand synthesis in stem/progenitor cells, fostering proliferation through non-Smad pathways like mTOR and NF-κB. The gene discussed is MTOR; the disease is central nervous system cancer.